Assembly Biosciences (NASDAQ:ASMB) Downgraded by BidaskClub

BidaskClub downgraded shares of Assembly Biosciences (NASDAQ:ASMB) from a sell rating to a strong sell rating in a research note released on Tuesday, BidAskClub reports.

Several other equities research analysts have also issued reports on ASMB. Chardan Capital reissued a hold rating on shares of Assembly Biosciences in a research note on Sunday, June 30th. Zacks Investment Research lowered shares of Assembly Biosciences from a buy rating to a hold rating in a research note on Wednesday, July 10th. Finally, William Blair reissued a buy rating on shares of Assembly Biosciences in a research note on Tuesday, July 16th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company’s stock. Assembly Biosciences has an average rating of Hold and an average price target of $41.20.

NASDAQ:ASMB traded down $0.58 during mid-day trading on Tuesday, hitting $12.12. The company’s stock had a trading volume of 4,609 shares, compared to its average volume of 233,198. Assembly Biosciences has a 1 year low of $11.78 and a 1 year high of $44.54. The company has a current ratio of 7.97, a quick ratio of 7.97 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $324.49 million, a PE ratio of -3.08 and a beta of 1.46. The business’s fifty day moving average price is $13.62.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.01. Assembly Biosciences had a negative net margin of 671.48% and a negative return on equity of 56.45%. The company had revenue of $3.89 million for the quarter, compared to analyst estimates of $3.81 million. On average, equities research analysts predict that Assembly Biosciences will post -4.34 EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. boosted its stake in shares of Assembly Biosciences by 3.4% during the 4th quarter. BlackRock Inc. now owns 1,909,510 shares of the biopharmaceutical company’s stock worth $43,193,000 after acquiring an additional 63,554 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of Assembly Biosciences by 0.4% during the 2nd quarter. Janus Henderson Group PLC now owns 956,634 shares of the biopharmaceutical company’s stock worth $12,905,000 after acquiring an additional 3,749 shares in the last quarter. Victory Capital Management Inc. boosted its stake in shares of Assembly Biosciences by 5.9% during the 1st quarter. Victory Capital Management Inc. now owns 562,399 shares of the biopharmaceutical company’s stock worth $11,074,000 after acquiring an additional 31,490 shares in the last quarter. Emerald Advisers LLC boosted its stake in shares of Assembly Biosciences by 20.3% during the 1st quarter. Emerald Advisers LLC now owns 468,379 shares of the biopharmaceutical company’s stock worth $9,222,000 after acquiring an additional 79,039 shares in the last quarter. Finally, FMR LLC boosted its stake in shares of Assembly Biosciences by 0.6% during the 1st quarter. FMR LLC now owns 445,716 shares of the biopharmaceutical company’s stock worth $8,776,000 after acquiring an additional 2,680 shares in the last quarter. 86.16% of the stock is currently owned by institutional investors and hedge funds.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Featured Story: Momentum Indicators

Analyst Recommendations for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.